Wong Charlene, Berkowitz Zahava, Saraiya Mona, Wideroff Louise, Benard Vicki B
Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Sex Health. 2010 Sep;7(3):338-45. doi: 10.1071/SH09115.
US cervical cancer screening recommendations have not changed since the human papillomavirus (HPV) vaccine introduction in 2006, but epidemiological and cost-effectiveness studies indicate that recommendations will need to change for fully vaccinated women. We evaluated physician intentions regarding HPV vaccine's impact on future screening.
A nationally representative sample of 1212 primary care physicians was surveyed in 2006-2007 (response rate: 67.5%). Our study included 1114 physicians who provided Pap testing. Questions covered Pap test screening practices and intentions regarding HPV vaccine's impact on screening. Distribution differences were assessed using chi(2) statistics; multivariate analyses were performed.
Overall, 40.7% (95% confidence interval (CI): 37.6-43.8%) of physicians agreed that the HPV vaccine will affect screening initiation, and 38.2% (35.0-41.5%) agreed that vaccination will affect screening frequency. Significant differences in responses were found by specialty; internists were more likely to agree that vaccination would impact screening than other specialties. Belief in the effectiveness of new screening technologies was associated with intention to change screening initiation (odds ratio (OR) = 1.66 (1.20-2.31)) and frequency (OR = 1.99 (1.40-2.83)). Adherence to current Pap test screening interval guidelines was associated with intention to change screening frequency (OR = 1.39 (1.01-1.91)).
Many providers anticipate adjusting screening for vaccinated women, but a significant group believes nothing will change or are unsure. The present study provides important baseline data on intentions in the period preceding widespread vaccine diffusion and may help explain current and future trends in practice patterns.
自2006年引入人乳头瘤病毒(HPV)疫苗以来,美国宫颈癌筛查建议一直未变,但流行病学和成本效益研究表明,对于完全接种疫苗的女性,筛查建议需要改变。我们评估了医生关于HPV疫苗对未来筛查影响的意向。
2006 - 2007年对1212名初级保健医生进行了全国代表性抽样调查(回复率:67.5%)。我们的研究纳入了1114名提供巴氏试验的医生。问题涵盖巴氏试验筛查实践以及关于HPV疫苗对筛查影响的意向。使用卡方统计评估分布差异;进行多变量分析。
总体而言,40.7%(95%置信区间(CI):37.6 - 43.8%)的医生同意HPV疫苗将影响筛查起始,38.2%(35.0 - 41.5%)同意接种疫苗将影响筛查频率。按专业发现回复存在显著差异;内科医生比其他专业更有可能同意接种疫苗会影响筛查。对新筛查技术有效性的信念与改变筛查起始意向(优势比(OR)= 1.66(1.20 - 2.31))和频率(OR = 1.99(1.40 - 2.83))相关。遵循当前巴氏试验筛查间隔指南与改变筛查频率意向(OR = 1.39(1.01 - 1.91))相关。
许多医疗服务提供者预计会调整对接种疫苗女性的筛查,但相当一部分人认为不会有变化或不确定。本研究提供了疫苗广泛普及之前这段时期意向的重要基线数据,可能有助于解释当前和未来的实践模式趋势。